- U.S. patent granted for autologous tissue patch manufacturing technology based on 'cryo-solidification'
- Customized regeneration patches achievable through physical cooling process alone, reinforcing global technology protection
- Platform expansion foundation secured for diabetic foot, skin regeneration, and chronic wound applications

ROKIT Healthcare (KOSDAQ: 376900), an AI-driven hyper-personalized organ regeneration platform company, has received approval for U.S. patent registration covering its autologous tissue-based tissue regeneration patch manufacturing technology, strengthening its global intellectual property competitiveness.

The patent, titled "Method of Manufacturing a Tissue Regeneration Patch," pertains to a technology for manufacturing wound-customized regeneration patches based on a patient's own autologous tissue.

The patented technology involves micronizing a patient's own adipose-derived autologous tissue and then using a physical cooling process to freeze and solidify the material into a wound-customized regeneration patch. The company believes this process enhances the preservation of key components in autologous tissue — including extracellular matrix and growth factors — while enabling the production of individually customized patches tailored to the area and depth of each patient's wound.

The technology serves as a foundational platform applicable to skin regeneration fields where wound size and morphology vary by patient, including diabetic foot ulcers, burns, skin defects, and chronic wounds. ROKIT Healthcare has been developing optimized regeneration solutions for patient-specific wound sites by combining AI-based wound analysis, 3D modeling, autologous tissue-based bioinks, and 3D bioprinting technologies into an integrated organ regeneration platform.

This U.S. patent approval is expected to strengthen the technology protection foundation and competitive barriers for ROKIT Healthcare's global organ regeneration platform business. The physical cooling-based manufacturing technology requires the organic integration of multiple process elements — including cooling temperature conditions, tissue preservation, patch shape maintenance, and customized mold application — making it technically and intellectually complex to replicate. As a result, it is expected to raise both technical and IP barriers for late entrants attempting to develop or commercialize similar technologies.

The patent approval is also significant in that it reinforces ROKIT Healthcare's technology protection framework targeting the U.S. wound care and chronic wound regenerative medicine market. The company has designated diabetic foot regeneration as its primary application area, with plans to expand into chronic wounds, skin defects, burns, and other regenerative medicine fields going forward.

Additionally, the patent approval is expected to positively support ROKIT Healthcare's efforts to expand its North American business presence and enhance the value of its global platform. The company is advancing commercialization of its organ regeneration platform across key markets including the United States, South Korea, the Middle East, South America, and China, with a strategy that pairs technology protection with global business expansion through a growing patent portfolio.

ROKIT Healthcare recorded a 118% year-over-year revenue growth rate in the first quarter of this year, demonstrating strong top-line momentum. The company continues to build its foundation as an organ regeneration platform business by expanding its global patent portfolio alongside existing business performance.

A ROKIT Healthcare spokesperson commented, "The U.S. patent approval for our physical cooling-based tissue regeneration patch manufacturing technology carries great significance, as it affirms the technological differentiation and protectability of our approach in the U.S. market. Building on our portfolio of over 170 patents, we will continue to expand the application of our personalized regenerative medicine solutions across global markets including the United States, South Korea, the Middle East, South America, and China."